Results 171 to 180 of about 941,634 (294)

Gastritis cystica profunda occurring under immunosuppression: A case report of a patient with autoimmune hepatitis. [PDF]

Medicine (Baltimore)
He HM, Xu SY, Liu YC, Ji HZ, Bian ZL.
europepmc   +1 more source

Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain

Alimentary Pharmacology &Therapeutics, EarlyView.
Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez, Claudia Ferreira‐Tata, Isabel Viciana, Carolina Freyre‐Carrillo, Pedro Lopez‐Lopez, Ana Belen Perez, Berta Becerril‐Carral, Ana Fuentes, Juan Macías, Lucia Rios‐Muñoz, Francisco Franco‐Alvarez de Luna, María Teresa Cabezas‐Fernandez, Diana Corona‐Mata, Antonio Rivero‐Juarez, Antonio Rivero   +14 more
wiley   +1 more source

Progressive Pulmonary Cystic Disease in Autoimmune Hepatitis and Rheumatoid Arthritis: A Rare Association. [PDF]

Cureus
Kantheti HS, Huynh KT, Kanase N, Amar MH, Srinivasan L.   +4 more
europepmc   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

Atypical autoimmune hepatitis presenting as acute hepatitis with prominent cholestatic features: a case report. [PDF]

Front Immunol
Yang X, Cui J, Xu Z, Zheng X, Zhan Y, Lv T, Zhao X, Ren J.   +7 more
europepmc   +1 more source

Long‐Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long‐Term Safety Extension

Alimentary Pharmacology &Therapeutics, EarlyView.
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus, Frederik Nevens, Kris V. Kowdley, Alan Bonder, Thomas Capozza, Jing Li, Radhika Nair, Michael Trauner, David E. Jones   +8 more
wiley   +1 more source

Clinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study. [PDF]

J Korean Med Sci
Ahn JE, Ko JS, Moon JS, Choi S, Lee YJ, Lee EJ, Koh H, Choi HJ, Oh SH, Kim KM, Kang KS, Choe BH, Kim SH, Kim ES, Kim MJ, Kim SY, Lee KJ.   +16 more
europepmc   +1 more source

Hepatitis C and autoimmune hepatitis [PDF]

Hepatology, 2000
openaire   +2 more sources

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, EarlyView.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis. [PDF]

Hepatol Commun
Laschtowitz A, Vom Endt C, Kluge M, Pohl J, Frohme J, Wiering L, Vonderlin J, Greverath LM, Horn P, Püngel T, Zöllner C, Benckert J, Engelmann C, Roßner F, Demir M, Tacke F, Peiseler M.   +16 more
europepmc   +1 more source